Equities Analysts Offer Predictions for VNDA FY2026 Earnings

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Research analysts at HC Wainwright raised their FY2026 EPS estimates for shares of Vanda Pharmaceuticals in a research report issued to clients and investors on Monday, November 2nd. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will earn ($2.45) per share for the year, up from their previous estimate of ($3.03). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($2.68) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q4 2026 earnings at ($0.23) EPS, Q1 2027 earnings at ($0.32) EPS, Q2 2027 earnings at ($0.30) EPS, Q3 2027 earnings at ($0.24) EPS, Q4 2027 earnings at ($0.16) EPS and FY2027 earnings at ($1.02) EPS.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, October 28th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.31. The company had revenue of $69.81 million for the quarter, compared to the consensus estimate of $69.20 million. Vanda Pharmaceuticals had a negative net margin of 119.87% and a negative return on equity of 62.70%.

A number of other equities research analysts have also recently commented on the company. Wall Street Zen upgraded Vanda Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Thursday, October 15th. Zacks Research downgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 6th. Oppenheimer assumed coverage on shares of Vanda Pharmaceuticals in a research report on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 price objective for the company. Finally, B. Riley Financial reiterated a “buy” rating and issued a $12.00 target price (down from $17.00) on shares of Vanda Pharmaceuticals in a research note on Monday, August 10th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Vanda Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $13.50.

Vanda Pharmaceuticals Stock Down 3.4%

NASDAQ VNDA opened at $3.75 on Wednesday. The firm’s 50 day moving average price is $4.73 and its 200-day moving average price is $6.18. The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 0.01. Vanda Pharmaceuticals has a 52-week low of $3.64 and a 52-week high of $9.94.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Hsbc Holdings PLC raised its position in Vanda Pharmaceuticals by 8.8% in the first quarter. Hsbc Holdings PLC now owns 38,855 shares of the biopharmaceutical company’s stock valued at $261,000 after purchasing an additional 3,144 shares during the period. Quantbot Technologies LP purchased a new position in shares of Vanda Pharmaceuticals during the 2nd quarter worth $29,000. Legal & General Group Plc purchased a new position in shares of Vanda Pharmaceuticals during the 2nd quarter worth $34,000. Allworth Financial LP acquired a new stake in shares of Vanda Pharmaceuticals during the 2nd quarter worth about $43,000. Finally, SG Americas Securities LLC increased its position in shares of Vanda Pharmaceuticals by 94.7% during the 1st quarter. SG Americas Securities LLC now owns 21,042 shares of the biopharmaceutical company’s stock worth $145,000 after purchasing an additional 10,235 shares during the last quarter. 88.14% of the stock is owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.